pT3-EF1A-MYC-IRES-lucOS Citations (5)
Originally described in: beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma.Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi AD, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst AO, Monga SP, Brown BD, Villanueva A, Llovet JM, Merad M, Lujambio A Cancer Discov. 2019 Jun 11. pii: 2159-8290.CD-19-0074. doi: 10.1158/2159-8290.CD-19-0074. PubMed Journal
Articles Citing pT3-EF1A-MYC-IRES-lucOS
| Articles |
|---|
| Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. PubMed |
| NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma. Lindblad KE, Donne R, Liebling I, Barcena-Varela M, Lozano A, Ruiz de Galarreta M, Dhainaut M, Param NJ, Giotti B, Cappuyns S, Kodama T, Wang Y, Kamphorst AO, Tsankov AM, Lujambio A. Cancer Discov. 2025 Mar 3;15(3):495-510. doi: 10.1158/2159-8290.CD-24-1215. PubMed |
| PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis. Tzeng SF, Yu YR, Park J, von Renesse J, Hsiao HW, Hsu CH, Garnica J, Chen J, Chiu LT, Santol J, Chen TY, Chung PH, Kandalaft LE, Starlinger P, Hsieh RC, Yu MC, Hsiao PW, Carmona SJ, Chen HK, Meng Z, Lin YH, Zhou J, Tsai CH, Ho PC. Cancer Discov. 2025 Apr 28:OF1-OF21. doi: 10.1158/2159-8290.CD-24-1409. PubMed |
Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy.
Gong L, Luo J, Yang E, Ru B, Qi Z, Yang Y, Rani A, Purohit A, Zhang Y, Guan G, Paul R, Vu T, Chen Z, Ji R, Day CP, Wu C, Merlino G, Fitzgerald D, Altan-Bonnet G, Aldape K, Wu J, Guan X, Jiang P.
Cell. 2025 Jul 24:S0092-8674(25)00793-7. doi: 10.1016/j.cell.2025.07.004.
PubMed
Associated Plasmids |
| Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma. Lei MML, Leung CON, Leung RWH, Wu XQ, Chung KPS, Gu CYJ, Chan MSM, Chau WK, Mu QH, Ng KY, Tong M, Yun JP, Teo JMN, Ling GS, Wong PPC, Chan SL, Xiong ZW, Cheng ASL, Ding J, Ma S, Lee TKW. Nat Commun. 2025 Nov 11;16(1):9913. doi: 10.1038/s41467-025-64860-7. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.